Fosun Diagnostics to Market Miacom's Molecular Beacon Assays in Asia | GenomeWeb

NEW YORK (GenomeWeb) — Miacom Diagnostics and Fosun Diagnostics said today that they have partnered to market Miacom's molecular beacon-based diagnostic assays to the Chinese and broader Asian markets.

Under the agreement, Shanghai-based Fosun, the diagnostic division of Shanghai Fosun Pharmaceutical, will market Dusseldorf, Germany-based Miacom's proprietary multiplex assays for the detection of sepsis- and pneumonia-related pathogens.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.